Cargando…

NZ-GMP Approved Serum Improve hDPSC Osteogenic Commitment and Increase Angiogenic Factor Expression

Human dental pulp stem cells (hDPSCs), selected from the stromal-vascular fraction of dental pulp, are ecto-mesenchymal stem cells deriving from neural crests, successfully used in human bone tissue engineering. For their use in human therapy GMP procedures are required. For instance, the use of fet...

Descripción completa

Detalles Bibliográficos
Autores principales: Spina, Anna, Montella, Roberta, Liccardo, Davide, De Rosa, Alfredo, Laino, Luigi, Mitsiadis, Thimios A., La Noce, Marcella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990559/
https://www.ncbi.nlm.nih.gov/pubmed/27594842
http://dx.doi.org/10.3389/fphys.2016.00354
_version_ 1782448716818415616
author Spina, Anna
Montella, Roberta
Liccardo, Davide
De Rosa, Alfredo
Laino, Luigi
Mitsiadis, Thimios A.
La Noce, Marcella
author_facet Spina, Anna
Montella, Roberta
Liccardo, Davide
De Rosa, Alfredo
Laino, Luigi
Mitsiadis, Thimios A.
La Noce, Marcella
author_sort Spina, Anna
collection PubMed
description Human dental pulp stem cells (hDPSCs), selected from the stromal-vascular fraction of dental pulp, are ecto-mesenchymal stem cells deriving from neural crests, successfully used in human bone tissue engineering. For their use in human therapy GMP procedures are required. For instance, the use of fetal bovine serum (FBS) is strongly discouraged in clinical practice due to its high risk of prions and other infections for human health. Alternatively, clinical grade sera have been suggested, including the New Zealand FBS (NZ-FBS). Therefore, the aim of this study was to evaluate the behavior of hDPSCs expanded in culture medium containing NZ-FBS. Since it was widely demonstrated hDPSCs display relevant capabilities to differentiate into osteogenic and angiogenic lineages, we performed a comparative study to assess if these features are also retained by cultivating the cells with a safer serum never tested on this cell line. hDPSCs were grown using NZ-FBS and conventional (C-FBS) for 7, 14, and 21 days, in both 2D and 3D cultures. Growth curves, expression of bone-related markers, calcification and angiogenesis were evaluated. NZ-FBS induced significant cell growth with respect to C-FBS and promoted an earlier increase expression of osteogenic markers, in particular of those involved in the formation of mineralized matrix (BSP and OPN) within 14 days. In addition, hDPSCs cultured in presence of NZ-FBS were found to produce higher mRNA levels of the angiogenic factors, such as VEGF and PDGFA. Taken together, our results highlight that hDPSCs proliferate, enhance their osteogenic commitment and increase angiogenic factors in NZ-FBS containing medium. These features have also been found when hDPSC were seeded on the clinical-grade collagen I scaffold (Bio-Gide®), leading to the conclusion that for human therapy some procedures and above all the use of GMP-approved materials have no negative impact.
format Online
Article
Text
id pubmed-4990559
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-49905592016-09-02 NZ-GMP Approved Serum Improve hDPSC Osteogenic Commitment and Increase Angiogenic Factor Expression Spina, Anna Montella, Roberta Liccardo, Davide De Rosa, Alfredo Laino, Luigi Mitsiadis, Thimios A. La Noce, Marcella Front Physiol Physiology Human dental pulp stem cells (hDPSCs), selected from the stromal-vascular fraction of dental pulp, are ecto-mesenchymal stem cells deriving from neural crests, successfully used in human bone tissue engineering. For their use in human therapy GMP procedures are required. For instance, the use of fetal bovine serum (FBS) is strongly discouraged in clinical practice due to its high risk of prions and other infections for human health. Alternatively, clinical grade sera have been suggested, including the New Zealand FBS (NZ-FBS). Therefore, the aim of this study was to evaluate the behavior of hDPSCs expanded in culture medium containing NZ-FBS. Since it was widely demonstrated hDPSCs display relevant capabilities to differentiate into osteogenic and angiogenic lineages, we performed a comparative study to assess if these features are also retained by cultivating the cells with a safer serum never tested on this cell line. hDPSCs were grown using NZ-FBS and conventional (C-FBS) for 7, 14, and 21 days, in both 2D and 3D cultures. Growth curves, expression of bone-related markers, calcification and angiogenesis were evaluated. NZ-FBS induced significant cell growth with respect to C-FBS and promoted an earlier increase expression of osteogenic markers, in particular of those involved in the formation of mineralized matrix (BSP and OPN) within 14 days. In addition, hDPSCs cultured in presence of NZ-FBS were found to produce higher mRNA levels of the angiogenic factors, such as VEGF and PDGFA. Taken together, our results highlight that hDPSCs proliferate, enhance their osteogenic commitment and increase angiogenic factors in NZ-FBS containing medium. These features have also been found when hDPSC were seeded on the clinical-grade collagen I scaffold (Bio-Gide®), leading to the conclusion that for human therapy some procedures and above all the use of GMP-approved materials have no negative impact. Frontiers Media S.A. 2016-08-19 /pmc/articles/PMC4990559/ /pubmed/27594842 http://dx.doi.org/10.3389/fphys.2016.00354 Text en Copyright © 2016 Spina, Montella, Liccardo, De Rosa, Laino, Mitsiadis and La Noce. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Spina, Anna
Montella, Roberta
Liccardo, Davide
De Rosa, Alfredo
Laino, Luigi
Mitsiadis, Thimios A.
La Noce, Marcella
NZ-GMP Approved Serum Improve hDPSC Osteogenic Commitment and Increase Angiogenic Factor Expression
title NZ-GMP Approved Serum Improve hDPSC Osteogenic Commitment and Increase Angiogenic Factor Expression
title_full NZ-GMP Approved Serum Improve hDPSC Osteogenic Commitment and Increase Angiogenic Factor Expression
title_fullStr NZ-GMP Approved Serum Improve hDPSC Osteogenic Commitment and Increase Angiogenic Factor Expression
title_full_unstemmed NZ-GMP Approved Serum Improve hDPSC Osteogenic Commitment and Increase Angiogenic Factor Expression
title_short NZ-GMP Approved Serum Improve hDPSC Osteogenic Commitment and Increase Angiogenic Factor Expression
title_sort nz-gmp approved serum improve hdpsc osteogenic commitment and increase angiogenic factor expression
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990559/
https://www.ncbi.nlm.nih.gov/pubmed/27594842
http://dx.doi.org/10.3389/fphys.2016.00354
work_keys_str_mv AT spinaanna nzgmpapprovedserumimprovehdpscosteogeniccommitmentandincreaseangiogenicfactorexpression
AT montellaroberta nzgmpapprovedserumimprovehdpscosteogeniccommitmentandincreaseangiogenicfactorexpression
AT liccardodavide nzgmpapprovedserumimprovehdpscosteogeniccommitmentandincreaseangiogenicfactorexpression
AT derosaalfredo nzgmpapprovedserumimprovehdpscosteogeniccommitmentandincreaseangiogenicfactorexpression
AT lainoluigi nzgmpapprovedserumimprovehdpscosteogeniccommitmentandincreaseangiogenicfactorexpression
AT mitsiadisthimiosa nzgmpapprovedserumimprovehdpscosteogeniccommitmentandincreaseangiogenicfactorexpression
AT lanocemarcella nzgmpapprovedserumimprovehdpscosteogeniccommitmentandincreaseangiogenicfactorexpression